CORRECTION Open Access



## Correction to: AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial

David S. Lawrence<sup>1,2\*</sup>, Nabila Youssouf<sup>1,2</sup>, Síle F. Molloy<sup>3</sup>, Alexandre Alanio<sup>4</sup>, Melanie Alufandika<sup>5</sup>, David R. Boulware<sup>6,7</sup>, Timothée Boyer-Chammard<sup>4</sup>, Tao Chen<sup>8</sup>, Francoise Dromer<sup>4</sup>, Admire Hlupeni<sup>9</sup>, William Hope<sup>10</sup>, Mina C. Hosseinipour<sup>11</sup>, Cecilia Kanyama<sup>11</sup>, Oliver Lortholary<sup>4</sup>, Angela Loyse<sup>3</sup>, David B. Meya<sup>6</sup>, Mosepele Mosepele<sup>2,12</sup>, Conrad Muzoora<sup>6</sup>, Henry C. Mwandumba<sup>5,8</sup>, Chiratidzo E. Ndhlovu<sup>9</sup>, Louis Niessen<sup>8</sup>, Charlotte Schutz<sup>13</sup>, Katharine E. Stott<sup>5,10</sup>, Duolao Wang<sup>8</sup>, David G. Lalloo<sup>8</sup>, Graeme Meintjes<sup>13</sup>, Shabbar Jaffar<sup>8</sup>, Thomas S. Harrison<sup>3</sup> and Joseph N. Jarvis<sup>1,2</sup>

## Correction to: Trials (2018) 19:649 https://doi.org/10.1186/s13063-018-3026-4

Following publication of the original article [1], we have been notified that one of the author names was listed incorrectly. Both incorrect and correct author names are presented below. The original publication has been corrected.

- Originally published name: Sile L F Molloy
- Correct name: Sile F Molloy

## Author details

<sup>1</sup>Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.

<sup>2</sup>Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.

<sup>3</sup>Research Centre for Infection and Immunity, St George's University of London, London, UK.

<sup>4</sup>Molecular Mycology Unit and National Reference Centre for Invasive Mycoses, Institut Pasteur, Paris, France.

<sup>5</sup>Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.

<sup>6</sup>Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

<sup>7</sup>Department of Medicine, University of Minnesota, Minneapolis, MN, USA. <sup>8</sup>Department of Clinical Sciences and International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK. <sup>9</sup>Department of Medicine, University of Zimbabwe College of Health Sciences, Parirenyatwa Hospital, Harare, Zimbabwe. <sup>10</sup>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. <sup>11</sup>Lilongwe Medical Relief Trust (UNC Project), Lilongwe, Malawi. <sup>12</sup>Department of Internal Medicine, University of Botswana, Gaborone, Botswana. <sup>13</sup>Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Cape Town, South Africa.

Received: 28 December 2018 Accepted: 28 December 2018 Published online: 14 January 2019

## Reference

Lawrence DS, et al. AMBIsome Therapy Induction Optimisation (AMBITION):
 High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in
 sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled
 Non-Inferiority Trial. Trials. 2018;19:649. https://doi.org/10.1186/s13063-018-3026-4.

<sup>&</sup>lt;sup>1</sup>Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK <sup>2</sup>Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: david.s.lawrence@lshtm.ac.uk